SELLAS Life Sciences Group Inc sell daimler1
Start price
29.12.25
/
50%
€2.50
Target price
29.12.26
-
Performance (%)
72.00%
End price
04.01.26
€4.30
Summary
This prediction ended on 04.01.26 with a price of €4.30. The price for SELLAS Life Sciences Group Inc massively increased, which is bad news for the SELL prediction by daimler1. daimler1 has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w |
|---|---|
| SELLAS Life Sciences Group Inc | -0.679% |
| iShares Core DAX® | 1.130% |
| iShares Nasdaq 100 | 1.128% |
| iShares Nikkei 225® | 2.610% |
| iShares S&P 500 | -0.006% |
Comments by daimler1 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Sell SELLAS Life Sciences Group Inc